0001437749-13-011900.txt : 20130912 0001437749-13-011900.hdr.sgml : 20130912 20130912070101 ACCESSION NUMBER: 0001437749-13-011900 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20130912 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20130912 DATE AS OF CHANGE: 20130912 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PDL BIOPHARMA, INC. CENTRAL INDEX KEY: 0000882104 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943023969 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19756 FILM NUMBER: 131092243 BUSINESS ADDRESS: STREET 1: 932 SOUTHWOOD BLVD CITY: INCLINE VILLAGE STATE: NV ZIP: 89451 BUSINESS PHONE: 775-832-8500 MAIL ADDRESS: STREET 1: 932 SOUTHWOOD BLVD CITY: INCLINE VILLAGE STATE: NV ZIP: 89451 FORMER COMPANY: FORMER CONFORMED NAME: PROTEIN DESIGN LABS INC/DE DATE OF NAME CHANGE: 19930328 8-K 1 pdli20130910_8k.htm FORM 8-K pdli20130910_8k.htm

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): September 12, 2013

 

PDL BioPharma, Inc.

 

(Exact name of Company as specified in its charter)

 

000-19756
(Commission File Number)

 

 

 

 

Delaware

 

94-3023969

(State or Other Jurisdiction of

 

(I.R.S. Employer Identification No.)

Incorporation)

 

 

 

932 Southwood Boulevard
Incline Village, Nevada 89451
(Address of principal executive offices, with zip code)

 

(775) 832-8500
(Company’s telephone number, including area code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 
 
 

 

Item 8.01 Other Events.

 

On September 12, 2013, PDL BioPharma, Inc. issued a press release announcing that it has paid the September 12, 2013, regular quarterly dividend payment. The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits.

 

Exhibit No.

  

Description

99.1

  

Press Release

 

 

 

 
 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

  PDL BioPharma, inc.
(Company)		  
       
        
  By: /s/ Peter S. Garcia  
    Peter S. Garcia  
    Vice President and Chief Financial Officer  

 

Dated: September 12, 2013

 

 

 
 
 

 

Exhibit Index

 

Exhibit No.

  

Description

99.1

  

Press Release

 

 

 

 EX-99 2 ex99-1.htm EXHIBIT 99.1 ex99-1.htm

Exhibit 99.1

 

 

Contacts:

 

Peter S. Garcia

Jennifer Williams

PDL BioPharma, Inc.

Cook Williams Communications, Inc.

775-832-8500

360-668-3701

peter.garcia@pdl.com

jennifer@cwcomm.org

 

 

PDL BioPharma Completes Regular Quarterly Dividend Payment

 

INCLINE VILLAGE, NV, September 12, 2013 -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has paid the September 12, 2013, regular quarterly dividend payment of $0.15 per share to all stockholders owning shares of PDL as of September 5, 2013, the record date.

 

About PDL BioPharma

 

PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. Today, PDL is focused on intellectual property asset management, investing in new income generating assets and maximizing value for its shareholders. For more information, please visit www.pdl.com.

 

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.

 

 

###

 GRAPHIC 3 logo.jpg begin 644 logo.jpg M_]C_X``02D9)1@`!`@$`2`!(``#_[0N>4&AO=&]S:&]P(#,N,``X0DE-`^T` M`````!``2`````$``0!(`````0`!.$))300-```````$````>#A"24T#\P`` M````"```````````.$))300*```````!```X0DE-)Q````````H``0`````` M```".$))30/U``````!(`"]F9@`!`&QF9@`&```````!`"]F9@`!`*&9F@`& M```````!`#(````!`%H````&```````!`#4````!`"T````&```````!.$)) M30/X``````!P``#_____________________________`^@`````________ M_____________________P/H`````/____________________________\# MZ`````#_____________________________`^@``#A"24T$`````````@`! M.$))300"```````$`````#A"24T$"```````$`````$```)````"0``````X M0DE-!!0```````0````".$))300,``````GO`````0```'`````R```!4``` M0:````G3`!@``?_8_^``$$I&248``0(!`$@`2```_^X`#D%D;V)E`&2````` M`?_;`(0`#`@("`D(#`D)#!$+"@L1%0\,#`\5&!,3%1,3&!$,#`P,#`P1#`P, M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`$-"PL-#@T0#@X0%`X.#A04#@X. M#A01#`P,#`P1$0P,#`P,#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P, M_\``$0@`,@!P`P$B``(1`0,1`?_=``0`!__$`3\```$%`0$!`0$!```````` M``,``0($!08'"`D*"P$``04!`0$!`0$``````````0`"`P0%!@<("0H+$``! M!`$#`@0"!0<&"`4###,!``(1`P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S M-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4 MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1``("`0($ M!`,$!08'!P8%-0$``A$#(3$2!$%187$B$P4R@9$4H;%"(\%2T?`S)&+A7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:``P#`0`"$0,1`#\` M]56=G?6#I/3\_&Z?EY#:\G+_`)MAX'9AM=]&KU7_`*.KU/YRQ9_UK^ME'0J? M0I#;NI7-FFD_18WC[1D;?\%^XSZ=_P#VY97Y9D7795UN1EV&^Z\[KK'ZEQ\_ MS=NWVL9]"MBGQ8.(7+0=%/MF=ELPL2S*>TO;6`2UL29(;W^*R?\`G;B_]Q[? M^C_Y)9?U2/7.K_5J_&S?Y@@-P,NTDOL:#,6-^D^IFW97D_X3_A/YRP6#@^IU M6O`RVNK) MH$MI<6V@2:GC:Z/WA^]_851WU5Z:6D-=:UQ&CM\P?ZKER^^W$R/4KQME9X@ZCUZCI^2,>RI[ MW%@?N;MB"7-_.M=+:ZRU_NS,82YSH&WU\? M^6UC??1^?_@OTG\[P7M>W0RUPY"]X7)]7_Q?8/4.K,S:;#C46N+LZA@^F>=] M#O\``/M=_/\`_;G\\K.+/0X9]-C^Q2_U0^LV5E]$NOZE4X,P88,MK0&7`>W: MRMNW]-7_`#=NS]#_`.>ZZ>3U7,R<\9K3Z5K);2UH#BQNOMX/J.]WO73YW36_ ML=_3\"ME;6L:RFL>UH#2WV_@LKI70NHXO4:,BYK!767%Q#I.K'LXV_O.4$R# M(D"@>BG.?U?K+V%CK[=KM##`T_YS:VN4NE]%R]K3$-UAQ3=YT&07GP_E+/_P";/5?W*_\`/_\`,4E/ M3_M/IO\`W+I_[<;_`.21:;Z;V;Z+&VLF-S"'"1VEJY/_`)L]5_;'/`:9$&/@DI__]'U5))))3C?7#+R\+ZM9V5AV&G)J8TU MV-B0=[&_GAS5A_5SK'4,CKM&+B=3LZO@FES^HF^IE1H?MFGT;&LQWW^I;[/; M79LK71?67I=_5^AY?3<=[:[MY'5^G=0ZO=B MM9TEKFXU>(U^]Y>STG>M=E3'IGUCZ?@=#RL^VS-R&- MSK<=C,AS;KWVEVQN/B^GM;Z6[^9K=_-K1Z?]8VY/4?V5G8=W3<]]9NIJN-;Q M96-'.JNQ[+J][/SZOIK+K^IN:.B689R:ZLZKJ+^IX5S`7,;9N+Z6W,?L<[VN MNMLOVO^C[&U[49#'ZC??S_J MJ>3Z=]9^L5X?3LFOK/V_J63D^C=T:QE3GFLV&OU!Z+*[Z/T3?5WV+8QOK#F= M/ZM]8C]GRNILQKF6>FQXV44MKEY;]IM8QFYV_P#04>]^Q;7U3Z"_HG2*L3*] M&S+8ZPONJ'(>]]C!O>UMGM8[:@T_5[-K=]8B;*B.LS]FC=[)J=1^G]O[Q_P: M,IP)D*%?]+U?U5-NSKSK.GXF=TS!OZBS-8+*VUFNO:PMW[K[,FRJNOG:JMGU MRPZNC7=5LQ[F?9,C[)E8SMF^NP.:RSW->ZJQC&O]3=79[UG7?4_JG[/Z)0'8 MF6>E4NJOPLK><6QS@&MO]C7;WU;?9ZU*9WU+ZC^P<_I;+<9K\O/9F5%C'5U- M8/0W4BEN_P!+;Z#FU5LW^S_"("./2SU_YO$IT;OK@W'&(S]$['_3^W]X_P"#0'MT+'X_UO\`O%.AD]:O&+B9/3NGW]1; MF5^LSTW55!C"*W,]9^7;2UK[/6_1U_\`&)^D]=JZKCU7X]%K6N?95>UX`=39 M4=CZ[=A>SZ7[CUBYGU3ZG8.DD'#S6=/PFXEN'FA[L?U`UC3F5,8'>I9[-FRZ MO^;6K]5NB9'1,&_%R+*[39DVWL=2W8W99MV-]+Z-6V/YMGL8@1`1T-E3_]+U M5)?*J22GZJ27RJDDI^JDE\JI)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?JI)?* MJ22G_]D`.$))300&```````'``$````!`0#_X@Q824-#7U!23T9)3$4``0$` M``Q(3&EN;P(0``!M;G1R4D="(%A96B`'S@`"``D`!@`Q``!A8W-P35-&5``` M``!)14,@0``9&5S8P`````````2D!\@'Z`@,"#`(4`AT")@(O`C@"00)+`E0"70)G`G$">@*$`HX"F`*B M`JP"M@+!`LL"U0+@`NL"]0,``PL#%@,A`RT#.`-#`T\#6@-F`W(#?@.*`Y8# MH@.N`[H#QP/3`^`#[`/Y!`8$$P0@!"T$.P1(!%4$8P1Q!'X$C`2:!*@$M@3$ M!-,$X03P!/X%#044%]@8&!A8& M)P8W!D@&609J!GL&C`:=!J\&P`;1!N,&]0<'!QD'*P<]!T\'80=T!X8'F0>L M![\'T@?E!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0"24).@E/"60) M>0F/":0)N@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI M"X`+F`NP"\@+X0OY#!(,*@Q##%P,=0R.#*<,P`S9#/,-#0TF#4`-6@UT#8X- MJ0W##=X-^`X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/E@^S#\\/[!`) M$"800Q!A$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F$D429!*$$J,2 MPQ+C$P,3(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.%/`5$A4T%585>!6; M%;T5X!8#%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$`891B*&*\8 MU1CZ&2`911EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;BANR&]H<`APJ M'%(<>QRC',P<]1T>'4<=:AZ4'KX>Z1\3'SX?:1^4'[\? MZB`5($$@;""8(,0@\"$<(4@A=2&A(B>K)]PH M#2@_*'$HHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K`BLV*VDKG2O1+`4L.2QN M+*(LURT,+4$M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<-]1B)&9T:K1O!' M-4=[1\!(!4A+2)%(UTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I-`DU* M39--W$XE3FY.MT\`3TE/DT_=4"=0<5"[40914%&;4>92,5)\4L=3$U-?4ZI3 M]E1"5(]4VU4H5755PE8/5EQ6J5;W5T17DE?@6"]8?5C+61I9:5FX6@=:5EJF M6O5;15N56^5<-5R&7-9=)UUX7&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A M]6))8IQB\&-#8Y=CZV1`9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E# M:9II\6I(:I]J]VM/:Z=K_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q M.G&5&YXS'DJ M>8EYYWI&>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_A'_E@$>`J($*@6N! MS8(P@I*"](-7@[J$'82`A..%1X6KA@Z&I+CDTV3 MMI0@E(J4])5?EAMJ(FHI:C!J-VH^:D5J3'I3BEJ:8:IHNF M_:=NI^"H4JC$J3>IJ:H_R#W(O,DZR;G*.,JWRS;+MLPUS+7--:6YQ_GJ>@RZ+SI M1NG0ZEOJY>MPZ_OLANT1[9SN*.ZT[T#OS/!8\.7Q)E\K.$ MP]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G M]Q$``@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1 M\#,D8N%R@I)#4Q5C+RLX3#TW7C M\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B7I[?'_]H`#`,! M``(1`Q$`/P#U5))<3]JJ=_I?WW_X/_C/YMT(& M9H*>T9978W=6X/;)$M((D':X:?NN4,C)HQJ_5O?L8#&XSR?@O*OJQ]9\GH>3 M#IMPK3^FI\/^%J_X3_SXN_ZUEX^;T-N5BO%M-KFN8\?%.R8C`]QW4W/V[TG_ M`+D-^YW_`)%+]N])_P"Y#?N=_P"17%*_^P^JG7[.?O;_`.24:GJ&=9Z6]VUN M2R3^]+1][]JN`@@$&0=00N$R<#,Q`#D5.K#N"=1][58_4%K7"=E/\`+NXL&*\RL?H+_P#T79^]4[_H M+RK-PLK`RK,3+K-=U9AS3_U3?WFN5SES'AH:'])23I/3,CJN?5@XY:++3])Q M@`#W/=_9:O6NE="P>F=-'3JV^I6Z3:Y_+W'Z3W?N\+QRJVRFQMM3BRQA#F/: M8((XG MW#:[=39)KD^X1^:Y=@VRO:/<./$+A*.GOH+FNML+=C002((=O_DKE%(4VDP&.)/``*V^B]!N-KW\UJ2DWUE#F]/Q0_Z0<`[X[5A87],H_P",9_U070?6S^BT?\8?R+GL M,AN70YQ@"QA)/$;@DI[Y9W7L2O(Z=:]P]](WL=W$?2_Z*M'.P@).14!X[V_W MK'ZYUO&=C.Q<9XM?9H]S?HAO];\YR2GFEUF=:;?JUZCC+G55EQ\Y9N7*`%Q# M6B2=`!XKK>I4FCZO.I/-==;3\0YFY)3R*[W"_H='_%L_ZD+@EVF)U/IS<6EK MLBL.;6T$%PT(`24Z"2J?M7IO_&^JGU&LIO\` MMO6:Q-3B*<8D.!+3_.V1[=G^C8NE^L;'OZ8X,:7'>W0"2M14>L]7QNCX1S>&@DQY)JG&^M-=C\6D,:7$6:P)[+F_LV1_HG_YI M6Q5_C"Z'8`]U63567;?5?6"T'XUV6*YU;ZST8%&#D8]8S*<^P,8]K]@`/Y_T M'[OZB?[<[`K=3S?V;(_T3_\`-*G5@9MQBNBQW]DQ]Z[Q),4X71_J^<>QN3F0 M;6ZLK&H:?WG']Y7NN-<[I5[6@N)#8`U/TFJ^DDIX#[-D?Z)_^:4OLV1_HG_Y MI7?I)*>`^S9'^B?_`)I5_H-%S>K4.=6YK1ODD$#Z#UV"22E))))*?__2]522 M224IT;6ZBQ_P"; M[?H+3R_J^,CKF%U9MWIMP6&L4!D[A[_\)O;L_G/]&I3.&FHVEL/3ZME.,RSJ M'UC^L&?A_;;L'!ZGY-XB]NQMC'_RMC_:UR-T;ZMLZ M:?FR+LEXC0_FL9+MO^<@91X>FPJ-:B7=3QWU?MZU?]7,KI73^G?: M:\FQX=E.>`UISZ>[U%:^L/3,CI70>B8&\.R:[W'=RT/>?4C^HQ MSUU?U;Z%^PL!V'Z_VC=:ZW?LV?2#&;=N^S]Q+K_0?VS]D_3^A]DM%OT-^Z(] MOTZ]J/NCCZ"-\5]]%.!U%O4^@]=Z2X=1R,MG4+?3R*[G2P^ZMC_3J'Z.MOZ? M]'_HU<^L>1AOZFW&?U#/9:VH?J/3@=TRYWJVEH=]-KF?HUI=;Z!^U:>LV]6Z7U#[%;DL%=X=4VT$`-;+- MY_X-B`E$\))J0!Z=>BG-^KO5,^WIW7<:ZZ]YP&N./;?+;VAS;MHM_/;8ST4_ MU,Q^K]0HQNJ9G4;GU8[K&,QRYSA8/?N?D/<[WNWV>S=_HEI=-^JOV`=4'VQU M_P"U&;7.>SW-,6-=8]V_]*YSKMW^"5[H'2/V-TRO`]7U_3+CZFW9.YQ?]#=9 MX_O)2G&I<-:D=/ZOJ4\9T8=8ZGT/J65;U3*8,(V64AEADO:SU"+;3-OI>QFR MO?\`RU-UG6LKZI_M^WJ>0R_'(;374[8PM;8*'.NV>ZVUTN]ZZ/I/U7_9O2<[ MIWVGU?MV_P#2^GMV[V>E]#U'[]O]=)GU7V_5AWU?^TSNG]8]/QL^T?S/J?V/ MYU$Y(WT^8=/T/TE(.H]2JM^KW3;\W/MP;